Ferric Gluconate Dosing for Severe Iron Deficiency Anemia

Standard Dosing Regimens

The American Journal of Kidney Diseases recommends administering 125 mg IV weekly for 8 consecutive weeks for hemodialysis patients, with a total cumulative dose of 1,000 mg 1, 2, 3
For non-hemodialysis patients, the manufacturer recommends not exceeding 125 mg per infusion 1, 3
For pediatric patients, weight-based dosing is recommended at 1.0 mg/kg weekly, not to exceed 125 mg per dose, with specific dosing regimens for children under 20 kg 2, 4

The American Journal of Kidney Diseases recommends infusing 125 mg in 50-100 mL saline over 30-60 minutes, with a standard rate of approximately 2.1-4.2 mg/min 1, 2, 3
No test dose is required for ferric gluconate, unlike iron dextran 5, 6, 7

The American Journal of Kidney Diseases recommends not measuring transferrin saturation or ferritin within 2-7 days after the last dose for doses of 100-125 mg 4
Target transferrin saturation should be greater than 20% and ferritin should be between 100-500 ng/mL for optimal erythropoiesis 1, 4

Ferric gluconate is less practical than newer formulations for severe anemia, with a maximum single dose of 125 mg compared to 750-1,000 mg for ferric carboxymaltose or ferric derisomaltose 5, 6, 8
Newer formulations that deliver 1,000 mg in 1-2 infusions are preferred when rapid iron repletion is needed 8

Ferric gluconate is significantly less expensive, with an approximate cost of $610 for 1,000 mg total dose, compared to $3,470 for ferric carboxymaltose or $3,896 for ferric derisomaltose 8

Ferric gluconate remains appropriate for hemodialysis patients, patients with cost constraints, and patients who have had reactions to iron dextran 1, 4, 8
Alternative IV iron formulations should be considered when rapid iron repletion is needed, patient cannot return for multiple infusion visits, or total iron deficit exceeds 1,000 mg 8

Do not exceed 125 mg per dose per manufacturer guidelines, though research supports 250 mg doses are safe in selected patients 1, 3
Do not measure iron studies too soon after infusion, as this creates spuriously elevated values 1, 3, 4
Do not use oral iron concurrently with IV iron therapy, as it is unnecessary and increases side effects without benefit 2, 4
Do not confuse ferric gluconate with iron dextran, as they have different dosing limits and safety profiles 5, 6, 1

Standard adult protocol: 125 mg ferric gluconate administered intravenously over 60 minutes, once weekly for 8 weeks (total cumulative dose ≈ 1,000 mg). No test dose is required. This regimen is the established standard for hemodialysis patients with iron‑deficiency anemia. 9
Manufacturer limit: The product label advises that individual infusions should not exceed 125 mg. 10

No test dose needed for ferric gluconate, in contrast to iron dextran which requires a 25 mg test dose; this confers a safety advantage over iron dextran formulations. 9

Therapeutic iron targets: Maintain transferrin saturation > 20 % and ferritin 100–500 ng/mL to support optimal erythropoiesis. 9
Upper safety thresholds: Withhold further iron therapy if transferrin saturation exceeds 50 % or ferritin exceeds 800 ng/mL to prevent iron overload. 9
Frequency of monitoring: Iron studies should be reassessed at least every 3 months during maintenance therapy. 9

Appropriate candidates: Adult hemodialysis patients who require ongoing iron supplementation are suitable for ferric gluconate therapy. 10
Cost consideration: Ferric gluconate is less expensive (≈ $610 for a 1,000 mg course) compared with newer IV iron agents ($3,470–$3,896 for equivalent dosing).

Practicality: Ferric gluconate is less practical for severe anemia requiring rapid repletion because it requires eight weekly visits, whereas newer agents (e.g., ferric carboxymaltose 750 mg per dose or ferric derisomaltose 1,000 mg per dose) can deliver the full 1,000 mg iron load in 1–2 infusions. 10

Lack of FDA endorsement: Ferric gluconate has not been established as safe and effective for pediatric hemodialysis patients according to FDA labeling. 9

Rare severe reactions: Anaphylaxis‑like reactions occur in fewer than 1 % of ferric gluconate administrations. 9
No reported fatalities: Unlike iron dextran, ferric gluconate has no documented treatment‑related deaths. 9
Administration setting: Infusions should be performed in a location staffed by personnel trained in emergency management, with immediate access to epinephrine, diphenhydramine, and corticosteroids. 9